 This is an investigational study. Ibrutinib is FDA approved and commercially available for the treatment of patients with MCL. Rituximab is FDA approved for the treatment of non-Hodgkins lymphoma and certain types of leukemia. Using these 2 drugs in combination with each other is investigational. All of the drugs in Part 2 are standard of care for the treatment of lymphoma. 